Marie-Christine Simon

Prof. Dr. Marie-Christine Simon

Department of Nutrition & Food Sciences, Nutrition & Microbiota, University of Bonn, Bonn, Germany
orcid

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Cell Host & Microbe
Verified
Journal Article
Open access
JRJosefine Roswall
Josefine Roswall
LOLisa M. Olsson
Lisa M. Olsson
PKPetia Kovatcheva-Datchary
Petia Kovatcheva-Datchary
SNStaffan Nilsson
Staffan Nilsson
VTValentina Tremaroli
Valentina Tremaroli
FBFredrik Bäckhed
Fredrik Bäckhed
The gut is inhabited by a densely populated ecosystem, the gut microbiota, that is established at birth. However, the succession by which different bacteria are incorporated into the gut microbiota is still relatively unknown. Here, we analyze the microbiota from 471 Swedish children followed from birth to 5 years of age, collecting samples after 4 and 12 months and at 3 and 5 years of age as well as from their mothers at birth using 16S rRNA gene profiling. We also compare their microbiota to an adult Swedish population. Genera follow 4 different colonization patterns during establishment where Methanobrevibacter and Christensenellaceae colonize late and do not reached adult levels at 5 years. These late colonizers correlate with increased alpha diversity in both children and adults. By following the children through age-specific community types, we observe that children have individual dynamics in the gut microbiota development trajectory.

17 June 2015 in Diabetes Care
Verified
Journal Article
Open access
PDF file
Marie-Christine SimonMarie-Christine Simon
Marie-Christine Simon
KSKlaus Strassburger
Klaus Strassburger
BNBettina Nowotny
Bettina Nowotny
HKHubert Kolb
Hubert Kolb
PNPeter Nowotny
Peter Nowotny
MRMichael Roden
Michael Roden
OBJECTIVE Ingestion of probiotics can modify gut microbiota and alter insulin resistance and diabetes development in rodents. We hypothesized that daily intake of Lactobacillus reuteri increases insulin sensitivity by changing cytokine release and insulin secretion via modulation of the release of glucagon-like peptides (GLP)-1 and -2. RESEARCH DESIGN AND METHODS A prospective, double-blind, randomized trial was performed in 21 glucose tolerant humans (11 lean: age 49 ± 7 years, BMI 23.6 ± 1.7 kg/m2; 10 obese: age 51 ± 7 years, BMI 35.5 ± 4.9 kg/m2). Participants ingested 1010 b.i.d. L. reuteri or placebo over 4 weeks. Oral glucose tolerance and isoglycemic glucose infusion tests were used to assess incretin effect and GLP-1 and GLP-2 secretion, and euglycemic-hyperinsulinemic clamps with [6,6-2H2]glucose were used to measure peripheral insulin sensitivity and endogenous glucose production. Muscle and hepatic lipid contents were assessed by 1H-magnetic resonance spectroscopy, and immune status, cytokines, and endotoxin were measured with specific assays. RESULTS In glucose tolerant volunteers, daily administration of L. reuteri increased glucose-stimulated GLP-1 and GLP-2 release by 76% (P < 0.01) and 43% (P < 0.01), respectively, compared with placebo, along with 49% higher insulin (P < 0.05) and 55% higher C-peptide secretion (P < 0.05). However, the intervention did not alter peripheral and hepatic insulin sensitivity, body mass, ectopic fat content, or circulating cytokines. CONCLUSIONS Enrichment of gut microbiota with L. reuteri increases insulin secretion, possibly due to augmented incretin release, but does not directly affect insulin sensitivity or body fat distribution. This suggests that oral ingestion of one specific strain may serve as a novel therapeutic approach to improve glucose-dependent insulin release.

1 November 2019 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
YKYanislava Karusheva
Yanislava Karusheva
TKTheresa Koessler
Theresa Koessler
KSKlaus Strassburger
Klaus Strassburger
DMDaniel Markgraf
Daniel Markgraf
LMLucia Mastrototaro
Lucia Mastrototaro
MRMichael Roden
Michael Roden
Epidemiological studies have shown that increased circulating branched-chain amino acids (BCAAs) are associated with insulin resistance and type 2 diabetes (T2D). This may result from altered energy metabolism or dietary habits. We hypothesized that a lower intake of BCAAs improves tissue-specific insulin sensitivity. This randomized, placebo-controlled, double-blinded, crossover trial examined well-controlled T2D patients receiving isocaloric diets (protein: 1 g/kg body weight) for 4 wk. Protein requirements were covered by commercially available food supplemented ≤60% by an AA mixture either containing all AAs or lacking BCAAs. The dietary intervention ensured sufficient BCAA supply above the recommended minimum daily intake. The patients underwent the mixed meal tolerance test (MMT), hyperinsulinemic-euglycemic clamps (HECs), and skeletal muscle and white adipose tissue biopsies to assess insulin signaling. After the BCAA- diet, BCAAs were reduced by 17% during fasting (P < 0.001), by 13% during HEC (P < 0.01), and by 62% during the MMT (P < 0.001). Under clamp conditions, whole-body and hepatic insulin sensitivity did not differ between diets. After the BCAA- diet, however, the oral glucose sensitivity index was 24% (P < 0.01) and circulating fibroblast-growth factor 21 was 21% higher (P < 0.05), whereas meal-derived insulin secretion was 28% lower (P < 0.05). Adipose tissue expression of the mechanistic target of rapamycin was 13% lower, whereas the mitochondrial respiratory control ratio was 1.7-fold higher (both P < 0.05). The fecal microbiome was enriched in Bacteroidetes but depleted of Firmicutes. Short-term dietary reduction of BCAAs decreases postprandial insulin secretion and improves white adipose tissue metabolism and gut microbiome composition. Longer-term studies will be needed to evaluate the safety and metabolic efficacy in diabetes patients.This trial was registered at clinicaltrials.gov as NCT03261362.

12 July 2014 in Diabetes Care
Verified
Journal Article
Closed access
BMBarbara Menart-Houtermans
Barbara Menart-Houtermans
RRRuth Rütter
Ruth Rütter
BNBettina Nowotny
Bettina Nowotny
JRJoachim Rosenbauer
Joachim Rosenbauer
CKChrysi Koliaki
Chrysi Koliaki
FGfor the German Diabetes Study Group
for the German Diabetes Study Group
OBJECTIVE: Altered immune reactivity precedes and accompanies type 1 and type 2 diabetes. We hypothesized that the metabolic phenotype relates to the systemic cellular immune status. RESEARCH DESIGN AND METHODS: A total of 194 metabolically well-controlled patients with type 1 diabetes (n = 62, mean diabetes duration 1.29 years) or type 2 diabetes (n = 132, 1.98 years) and 60 normoglycemic persons underwent blood sampling for automated white blood cell counting (WBC) and flow cytometry. Whole-body insulin sensitivity was measured with hyperinsulinemic-euglycemic clamp tests. RESULTS: Patients with type 2 diabetes had higher WBC counts than control subjects along with a higher percentage of T cells and activated T helper (Th) and cytotoxic T (Tc) cells but lower proportions of natural killer (NK) cells. In type 1 diabetes, the percentage of activated Th and Tc cells was also higher compared with control subjects, whereas the ratio of regulatory T (Treg) cells to activated Th cells was lower, suggesting diminished regulatory capacity. Parameters of glycemic control related positively to Treg cells only in type 2 diabetes. Upon age, sex, and body mass adjustments, insulin sensitivity correlated positively with monocytes, while circulating lipids correlated positively with T cell subsets in type 1 diabetes. CONCLUSIONS: Immune cell phenotypes showed distinct frequencies of occurrence in both diabetes types and associate with insulin sensitivity, glycemia, and lipidemia.

1 June 1980 in Diabetes
Verified
Journal Article
Closed access
PDF file
VLVéronique Lassmann
Véronique Lassmann
PVPhilippe Vague
Philippe Vague
BVBernard Vialettes
Bernard Vialettes
Marie-Christine SimonMarie-Christine Simon
Marie-Christine Simon
Plasma levels of pancreatic polypeptide (PP) were studied in a group of 22 normal and 22 obese subjects after an overnight fast. In a second group of 10 normal and 13 obese adults, PP secretion was stimulated by a protein-rich meal. The results indicate lower fasting PP values in the obese subjects and a decreased response during the second phase of the meal-induced secretion. This could suggest a possible role of PP in obesity.

20 September 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
EMEstefanía Márquez
Estefanía Márquez
PSPeter Stehle
Peter Stehle
Marie-Christine SimonMarie-Christine Simon
Marie-Christine Simon
Flavan-3-ols are the main contributors to polyphenol intake. Many varying beneficial health effects in humans have been attributed to them, including the prevention of cardiovascular disease and cancer. Nevertheless, the mechanisms by which these flavonoids could exert beneficial functions are not entirely known. Several in vitro studies and in vivo animal models have tried to elucidate the role of the specific colonic metabolites on the health properties that are attributed to the parent compounds since a larger number of ingested flavan-3-ols reach the colon and undergo there microbial metabolism. Many new studies about this topic have been performed over the last few years and, to the best of our knowledge, no scientific literature review regarding the bioactivity of all identified microbial metabolites of flavan-3-ols has been recently published. Therefore, the aim of this review is to present the current status of knowledge on the potential health benefits of flavan-3-ol microbial metabolites in humans while using the latest evidence on their biological activity.